Stomatin-like protein 2 (SLP-2) (SLP-2)

Stomatin-like protein 2 (SLP-2), encoded by the STOML2 gene, is a mitochondrial inner membrane protein that plays a pivotal role in organizing membrane microdomains and stabilizing respiratory chain supercomplexes (UniProt Q9UJZ1). Unlike other stomatin family members, SLP-2 lacks a transmembrane domain and anchors to the membrane through high-affinity binding to cardiolipin, a phospholipid essential for mitochondrial function (Christie et al., 2011, Journal of Biological Chemistry). By acting as a molecular scaffold, SLP-2 regulates the assembly of the mitochondrial translation machinery and the activity of the metalloprotease PARL, thereby influencing mitochondrial proteostasis and dynamics. In clinical oncology, SLP-2 is significantly upregulated in various solid tumors, including lung, breast, and esophageal cancers, where it is associated with increased metabolic activity, cell survival, and poor patient prognosis (Zhang et al., 2014, Oncology Reports). Its role in promoting the 'Warburg effect' and protecting cancer cells from apoptosis makes it an attractive candidate for therapeutic intervention. While no small-molecule inhibitors have reached clinical trials, experimental knockdown of SLP-2 has been shown to reduce tumor growth and enhance sensitivity to existing chemotherapies in preclinical models. However, therapeutic strategies must account for potential off-target effects on systemic mitochondrial health and T-cell mediated immunity, as SLP-2 is also involved in immunological synapse formation (Mitsopoulos et al., 2015, Journal of Immunology).

Other names

STOML2HSPC108Stomatin-like protein 2, mitochondrial

Inhibition of SLP-2 disrupts mitochondrial respiratory chain supercomplexes and cardiolipin-rich microdomains, leading to mitochondrial dysfunction and apoptosis in cancer cells.